A detailed history of Arrowstreet Capital, Limited Partnership transactions in Eli Lilly & CO stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 1,608,706 shares of LLY stock, worth $1.31 Billion. This represents 1.28% of its overall portfolio holdings.

Number of Shares
1,608,706
Previous 1,168,926 37.62%
Holding current value
$1.31 Billion
Previous $909 Million 60.16%
% of portfolio
1.28%
Previous 0.84%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$724.87 - $909.04 $319 Million - $400 Million
439,780 Added 37.62%
1,608,706 $1.46 Billion
Q1 2024

May 15, 2024

BUY
$592.2 - $792.28 $136 Million - $182 Million
229,255 Added 24.4%
1,168,926 $909 Million
Q4 2023

Feb 14, 2024

SELL
$525.19 - $619.13 $279 Million - $329 Million
-531,981 Reduced 36.15%
939,671 $548 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $39.2 Million - $54 Million
90,169 Added 6.53%
1,471,652 $790 Million
Q2 2023

Aug 14, 2023

SELL
$350.74 - $468.98 $23 Million - $30.8 Million
-65,688 Reduced 4.54%
1,381,483 $648 Million
Q1 2023

May 15, 2023

SELL
$310.63 - $364.82 $151 Million - $177 Million
-486,045 Reduced 25.14%
1,447,171 $497 Million
Q4 2022

Feb 14, 2023

SELL
$321.55 - $374.67 $177 Million - $206 Million
-549,575 Reduced 22.14%
1,933,216 $707 Million
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $322 Million - $367 Million
-1,086,020 Reduced 30.43%
2,482,791 $803 Million
Q2 2022

Aug 15, 2022

BUY
$278.73 - $327.27 $71.7 Million - $84.1 Million
257,098 Added 7.76%
3,568,811 $1.16 Billion
Q1 2022

May 13, 2022

BUY
$234.69 - $291.66 $275 Million - $342 Million
1,172,504 Added 54.81%
3,311,713 $948 Million
Q4 2021

Feb 14, 2022

BUY
$224.85 - $279.04 $244 Million - $303 Million
1,084,730 Added 102.87%
2,139,209 $591 Million
Q3 2021

Nov 12, 2021

BUY
$221.6 - $272.71 $219 Million - $270 Million
988,944 Added 1509.03%
1,054,479 $244 Million
Q2 2021

Aug 13, 2021

SELL
$180.55 - $233.54 $62.3 Million - $80.6 Million
-345,272 Reduced 84.05%
65,535 $15 Million
Q1 2021

May 14, 2021

SELL
$164.32 - $212.72 $70.9 Million - $91.8 Million
-431,735 Reduced 51.24%
410,807 $76.7 Million
Q4 2020

Feb 12, 2021

SELL
$130.46 - $172.63 $52.3 Million - $69.2 Million
-400,917 Reduced 32.24%
842,542 $142 Million
Q3 2020

Nov 12, 2020

BUY
$146.22 - $169.13 $50.2 Million - $58.1 Million
343,566 Added 38.18%
1,243,459 $184 Million
Q2 2020

Aug 12, 2020

BUY
$136.42 - $164.18 $91.9 Million - $111 Million
673,427 Added 297.36%
899,893 $148 Million
Q1 2020

May 15, 2020

BUY
$119.05 - $147.35 $13 Million - $16.1 Million
109,069 Added 92.91%
226,466 $31.4 Million
Q4 2019

Feb 13, 2020

SELL
$106.92 - $132.43 $115 Million - $142 Million
-1,074,974 Reduced 90.15%
117,397 $15.4 Million
Q3 2019

Nov 14, 2019

SELL
$106.79 - $116.16 $22.6 Million - $24.5 Million
-211,300 Reduced 15.05%
1,192,371 $133 Million
Q2 2019

Aug 14, 2019

BUY
$110.79 - $129.32 $86 Million - $100 Million
776,173 Added 123.69%
1,403,671 $156 Million
Q1 2019

May 15, 2019

SELL
$111.31 - $131.02 $182 Million - $214 Million
-1,636,116 Reduced 72.28%
627,498 $81.4 Million
Q4 2018

Feb 14, 2019

SELL
$105.9 - $118.64 $145 Million - $163 Million
-1,372,608 Reduced 37.75%
2,263,614 $262 Million
Q3 2018

Nov 14, 2018

BUY
$85.86 - $107.31 $105 Million - $132 Million
1,227,904 Added 50.99%
3,636,222 $390 Million
Q2 2018

Aug 14, 2018

BUY
$75.7 - $86.88 $5.6 Million - $6.43 Million
74,024 Added 3.17%
2,408,318 $206 Million
Q1 2018

May 14, 2018

BUY
$74.21 - $87.6 $90.1 Million - $106 Million
1,214,407 Added 108.44%
2,334,294 $181 Million
Q4 2017

Feb 09, 2018

BUY
$81.94 - $87.89 $61.7 Million - $66.2 Million
752,919 Added 205.17%
1,119,887 $94.6 Million
Q3 2017

Nov 14, 2017

BUY
$77.07 - $85.54 $28.3 Million - $31.4 Million
366,968
366,968 $31.4 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $771B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.